News & Events

• January 25, 2023
  

  C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform

  C-Path today announced that the European Medicines Agency (EMA) has issued a letter of support for the Duchenne Regulatory Science Consortium’s (D-RSC) Model-based Clinical Trial Simulation Platform for Duchenne Muscular Dystrophy (DMD).

• January 23, 2023
  

  C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals

      Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By combining C-Path’s unique global regulatory expertise and Mobilise-D’s focus on digital assessment of mobility, this mutually beneficial partnership aims to accelerate and improve the impact of these important initiatives that share common goals. The Critical Path for...
• December 8, 2022
  

  ‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases

  A new initiative to boost research and development into rare and paediatric diseases will launch today [Thursday 8 December] at the European Health Summit.

• December 7, 2022
  

  C-Path Receives Data Transfer from Network of Hospitals in Japan

  C-Path has received properly anonymized electronic patient record (EPR) data from three hospitals in the Neonatal Research Network of Japan — Nagano Children’s Hospital, Kyorin University and Osaka General Hospital. The collaboration comes from partnering with leading pediatric neonatologists, Dr. Tomohiko Nakamura, Dr. Kenichiro Hosoi and Dr. Hiroko Iwami at each site, respectively.

• November 2, 2022
  

  C-Path and Eisai Data Sharing Collaboration to Include Lennox-Gastaut Syndrome Registry and Clinical Trial Data

  TUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collaboration to significantly promote data sharing and incorporate Lennox-Gastaut Syndrome (LGS) clinical trial data, into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Lennox-Gastaut syndrome is a severe form of epilepsy with seizures occurring...